KNSA — Kiniksa Pharmaceuticals International, plc
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1730430 ·
United Kingdom
Last close
$54.21
Market Cap
$2.51B
52W High
$59.87
52W Low
$41.49
ADV30
524,002
Next earnings
2026-07-28
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 214,266,000 | 117,893,000 | 29,267,000 | 22,592,000 | 825,280,000 | 189,952,000 | 219,593,000 |
| Dec 2025 | 202,127,000 | 111,152,000 | 19,768,000 | 14,199,000 | 763,633,000 | 165,596,000 | 196,027,000 |
| Sep 2025 | 180,855,000 | 97,291,000 | 24,021,000 | 18,435,000 | 712,333,000 | 174,858,000 | 176,950,000 |
| Jun 2025 | 156,797,000 | 85,776,000 | 20,160,000 | 17,832,000 | 661,150,000 | 192,037,000 | 166,143,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$165,860,000
Investing CF
$-169,368,000
Financing CF
$36,328,000
CapEx
$-1,630,000
Dividends Paid
—
Buybacks
$-7,634,000
EPS Diluted TTM
$0.90
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-439,546,000
Inventory
$73,141,000
Receivables
$23,224,000
ST Investments
$278,141,000
EBIT TTM
$93,216,000
Pretax Income TTM
$105,984,000
Interest Exp TTM
—
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$754,044,992
EBITDA
$94,893,000
Free Cash Flow
$117,572,000
Enterprise Value
$3,564,790,272
Total Cash
$468,092,992
Total Debt
$9,025,000
Shares Out
46,303,276
Trailing EPS
$0.91
Book Value
$8.22
ROE
13.7%
ROA
8.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 677,564,000 | 77,221,000 | 59,005,000 | 763,633,000 | 196,027,000 | — | 137,985,000 |
| Dec 2024 | 423,239,000 | -45,616,000 | -43,193,000 | 580,553,000 | 142,117,000 | — | 25,689,000 |
| Dec 2023 | 270,259,000 | -25,196,000 | 14,084,000 | 526,322,000 | 87,483,000 | — | 13,301,000 |
| Dec 2022 | 220,180,000 | 9,773,000 | 183,363,000 | 459,672,000 | 63,523,000 | — | 5,807,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$1.76
Max Pain — expiry 2026-11-20 (volume-derived — Yahoo OI feed degraded)
max pain strike: $45.00 · spot: $54.21 · call volume: 398 · put volume: 5Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| VERA | Vera Therapeutics, Inc. | $2.51B | $35.01 | — |
| SUPN | SUPERNUS PHARMACEUTICALS, INC. | $2.53B | $43.58 | — |
| KLRA | Kailera Therapeutics, Inc. | $2.48B | $19.13 | — |
| RARE | Ultragenyx Pharmaceutical Inc. | $2.65B | $26.91 | — |
| IRON | Disc Medicine, Inc. | $2.68B | $70.21 | — |
News headlines (Yahoo Finance, 1h cache)
Kiniksa Pharmaceuticals International, plc (KNSA) Upgraded to Strong Buy: Here's What You Should Know
2026-06-16 16:00 · Yahoo
NTLA Posts Strong Additional Phase III Data From HAE Study, Stock Up
2026-06-16 14:17 · Yahoo
ALKS' Sleep Disorder Drug Gets Orphan Drug Tags in the U.S. & Europe
2026-06-16 14:15 · Yahoo
Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences
2026-05-29 20:01 · Yahoo
High Growth Tech Stocks in the US for May 2026
2026-05-26 17:38 · Yahoo
Kiniksa Pharmaceuticals Still Has Room to Run After 100% Rally
2026-05-23 11:50 · Yahoo
We Think Kiniksa Pharmaceuticals International's (NASDAQ:KNSA) Profit Is Only A Baseline For What They Can Achieve
2026-05-08 14:59 · Yahoo
Kiniksa Pharmaceuticals International (KNSA) Is Up 29.2% After Raising 2026 Net Product Revenue Guidance
2026-05-02 01:18 · Yahoo
Kiniksa Pharmaceuticals International (KNSA) Announces Q1 2026 Financial Results
2026-05-01 07:58 · Yahoo
Kiniksa Pharmaceuticals International PLC (KNSA) Q1 2026 Earnings Call Highlights: Robust ...
2026-04-29 07:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.